Tumor-specific antigens have also been targeted in several clinical trials reducing off-tumor toxicities—for instance, NCT04489862 is an early phase I study which aims to target α-PD-1 and MSLN in non-small cell lung cancer at Wuhan Union Hospital, China. The gene discussed is MSLN; the disease is neoplasm.